SCHEDULE: Vanguard Group Discloses 5.23% Stake in AnaptysBio Inc.

The Vanguard Group has reported a beneficial ownership of 5.23% in AnaptysBio Inc., holding 1,537,550 shares of common stock.

Summary

• The Vanguard Group has filed a Schedule 13G, indicating beneficial ownership of AnaptysBio Inc. common stock.
• Vanguard's aggregate beneficial ownership amounts to 1,537,550 shares.
• This stake represents 5.23% of AnaptysBio Inc.'s common stock class.
• Vanguard holds sole voting power over 0 shares and shared voting power over 21,564 shares.
• Vanguard holds sole dispositive power over 1,502,076 shares and shared dispositive power over 35,474 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership by a large institutional investor and does not inherently convey positive or negative sentiment about the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing reflects a standard disclosure by a large institutional asset manager, The Vanguard Group, regarding its passive investment stake in AnaptysBio Inc. Such disclosures are common for investment firms that cross the 5% ownership threshold in publicly traded companies, indicating a significant but non-controlling position.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Vanguard may be viewed positively by some investors as a vote of confidence or an indicator of liquidity, though it is a passive investment.

Key Dates

Keywords

AnaptysBio Inc., Vanguard Group, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Schedule 13G, ANAB